Aperio Group LLC raised its stake in Amgen Inc. (NASDAQ:AMGN) by 9.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 365,006 shares of the medical research company’s stock after buying an additional 30,467 shares during the period. Aperio Group LLC’s holdings in Amgen were worth $62,865,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bank of New York Mellon Corp increased its position in Amgen by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,555,356 shares of the medical research company’s stock valued at $1,403,676,000 after buying an additional 195,200 shares during the last quarter. Norges Bank purchased a new stake in shares of Amgen during the fourth quarter worth about $1,016,913,000. Schwab Charles Investment Management Inc. boosted its stake in shares of Amgen by 1.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 2,894,780 shares of the medical research company’s stock worth $474,947,000 after buying an additional 45,403 shares during the period. Bank of Montreal Can boosted its stake in shares of Amgen by 10.5% in the first quarter. Bank of Montreal Can now owns 2,837,456 shares of the medical research company’s stock worth $465,543,000 after buying an additional 269,586 shares during the period. Finally, UBS Asset Management Americas Inc. boosted its stake in shares of Amgen by 3.1% in the first quarter. UBS Asset Management Americas Inc. now owns 2,719,874 shares of the medical research company’s stock worth $446,250,000 after buying an additional 81,362 shares during the period. Institutional investors and hedge funds own 79.53% of the company’s stock.

Amgen Inc. (NASDAQ:AMGN) traded up 0.19% during midday trading on Friday, hitting $169.43. 1,571,584 shares of the stock traded hands. The stock has a 50-day moving average of $174.48 and a 200 day moving average of $167.49. The firm has a market cap of $123.63 billion, a PE ratio of 15.43 and a beta of 1.35. Amgen Inc. has a 52-week low of $133.64 and a 52-week high of $184.21.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, July 25th. The medical research company reported $3.27 EPS for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a net margin of 35.46% and a return on equity of 29.85%. The company had revenue of $5.81 billion for the quarter, compared to analysts’ expectations of $5.67 billion. During the same quarter in the prior year, the company posted $2.84 earnings per share. Amgen’s revenue for the quarter was up 2.1% compared to the same quarter last year. Equities analysts forecast that Amgen Inc. will post $12.57 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Thursday, August 17th will be given a $1.15 dividend. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a yield of 2.71%. Amgen’s payout ratio is currently 41.93%.

WARNING: This news story was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://theolympiareport.com/2017/08/12/aperio-group-llc-raises-stake-in-amgen-inc-nasdaqamgn-updated.html.

A number of brokerages have recently issued reports on AMGN. Cann reissued a “buy” rating and issued a $203.00 price objective (up from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. BMO Capital Markets cut shares of Amgen from an “outperform” rating to a “market perform” rating in a research note on Wednesday, July 26th. Deutsche Bank AG reissued a “hold” rating and issued a $174.00 price objective (up from $172.00) on shares of Amgen in a research note on Wednesday, July 26th. Oppenheimer Holdings, Inc. reissued an “outperform” rating and issued a $203.00 price objective (up from $189.00) on shares of Amgen in a research note on Wednesday, July 26th. Finally, Cowen and Company reissued an “outperform” rating and issued a $209.00 price objective on shares of Amgen in a research note on Saturday, July 22nd. One analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $186.64.

In other Amgen news, SVP Cynthia M. Patton sold 2,922 shares of the company’s stock in a transaction dated Wednesday, May 24th. The shares were sold at an average price of $154.40, for a total value of $451,156.80. Following the transaction, the senior vice president now owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.20% of the company’s stock.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.